Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Portfolio Pulse from
Arcturus Therapeutics (ARCT) reported a Q4 loss of $1.11 per share, missing the Zacks Consensus Estimate of a $0.34 loss. This is a significant increase from the $0.32 loss per share a year ago.
March 06, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcturus Therapeutics reported a larger-than-expected Q4 loss of $1.11 per share, missing the consensus estimate of $0.34. This marks a significant increase from the previous year's loss of $0.32 per share.
The significant miss on earnings estimates and the increase in loss per share compared to the previous year are likely to negatively impact investor sentiment and put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100